6505--XOFIGO (Radium Ra-223)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Michael E. DeBakey VA Medical Center (MEDVAMC) in Houston, Texas, is conducting a Sources Sought/Request for Information (RFI) to identify potential sources for XOFIGO Isotope (Radium Ra-223). This market research will inform the procurement strategy (e.g., set-aside, sole source, unrestricted) for a future solicitation. Responses are due by March 17, 2026, at 15:00 Central Time.
Purpose & Scope
The RFI seeks to gather information from industry to define the acquisition approach for providing single unit doses of Xofigo (Radium Ra-223) for the treatment of patients with castration-resistant prostate cancer. The anticipated requirement, as outlined in the draft Statement of Work (SOW), includes receiving orders, ensuring proper radiopharmaceutical dose activity ranges (+/- 20% of ordered dose), and delivering doses to the MEDVAMC Nuclear Medicine Department in Houston, Texas. Deliveries must occur at least 60 minutes before the specified calibration time, accompanied by a BioDose-compatible packing slip, and utilize a licensed courier for radioactive material transport. The contractor will also be responsible for providing training on Xofigo use and crediting MEDVAMC for unadministered doses. The estimated base year cost is $375,679.18, with a period of performance including a base year (October 1, 2025 – September 30, 2026) and four option years.
Contract Details
- Opportunity Type: Sources Sought / Request for Information (RFI)
- Product: 6ML Radium Ra-223 Dichloride Injection (XOFIGO), 1 JB
- NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing) with a $19.0M size standard
- PSC Code: 6505 (Drugs and Biologicals)
- Set-Aside: None specified (to be determined based on RFI responses)
Response Requirements
Interested vendors must provide comprehensive answers to the following:
- Confirmation of whether items are manufactured by a small or large business, with documentation.
- Compliance with the Non-Manufacturer Rule (NMR), with documentation.
- Status as an authorized distributor with OEM access, including an authorized distribution letter.
- Contractor information: name, contact details, company size, UEI#, and CAGE Code.
- Business size status (SB, SDVOSB, VOSB, HUBZone, or 8A concern) with proof.
- Identification of any existing Government Wide Agency Contracts (GWAC), GSA Schedule, Federal Supply Schedule (FSS), Indefinite Delivery Indefinite Quantity (IDIQ), or Blanket Purchase Agreement (BPA) under which services can be provided, including contract numbers.
- Estimated market research pricing for the required items.
Submission & Deadline
- Response Due: March 17, 2026, at 15:00 Central Time
- Submission Method: Email to frank.sanders1@va.gov
- Subject Line: "RFI 36C25626Q0501- XOFIGO Isotope (Radium Ra-223)"
- Format: Microsoft Word document, 8.5 x 11 inches, 12-point font, 1-inch margins.
Additional Notes
This is a Sources Sought notice for market research purposes only and does not constitute a request for quote, proposal, or bid. The government will not pay for information submitted. Vendors are responsible for monitoring Federal Contract Opportunities for any future solicitations.